FERRLECIT - FERRLECIT Highlights

FERRLECIT Highlights

CONSISTENT IV IRON DELIVERY FOR CONSISTENT ANEMIA OUTCOMES

Single-Dose Safety Study
The safety of single-dose administration of FERRLECIT has been evaluated by Michael et al. (Kidney Int. 2002;61:1830-1839) in the largest controlled prospective study ever carried out in the hemodialysis population.[6] In this study, the rate of serious adverse events with FERRLECIT was similar to that observed with placebo.[6]

Study Description
Objectives: (1) To compare the adverse event profile of FERRLECIT with that of placebo and iron dextran (through historical controls) and (2) to evaluate the safety of FERRLECIT when given as an IV push (12.5 mg/min)

Study Design: Novel, phase IV, multicenter, crossover, randomized, double-blind, placebo-controlled, single-dose safety study.

Study Population: 2534 FERRLECIT-naïve hemodialysis (HD) patients with or without previous iron dextran exposure. Patients concurrently using antihistamines or corticosteroids were excluded.

Study Protocol: Patients were randomized into one of two crossover treatment
schedules: FERRLECIT, or sodium ferric gluconate complex (SFGC), was administered at the rate of 125 mg IV push over 10 minutes at HD session 2 and placebo (10 mL bacteriostatic saline) at session 3 OR placebo at HD session 2 and FERRLECIT at HD session 3. No test dose was administered.

[ back to top ]

Study Results

•	Overall rate of serious adverse events was 0.6% for FERRLECIT and 0.5% for placebo (P = 0.845)
•	Rate of life-threatening adverse events with FERRLECIT was 0.04%
•	No cross-reactivity observed between FERRLECIT and iron dextran in patients previously treated with iron dextran
•	Discontinuation rate due to treatment-related adverse events was 0.04% for FERRLECIT and 0.04% for placebo (1/2534)
•	No relationship observed between incidence/severity of adverse reactions and concomitant ACE inhibitor therapy

Author's Conclusions

•	Administration of FERRLECIT is associated with a low incidence of potentially severe hypersensitivity reactions.
•	Overall rate of serious adverse events with FERRLECIT was 0.6% and 0.5% for placebo.
•	FERRLECIT does not require a test dose.
•	FERRLECIT can be administered IV push (12.5mg/min)

[ back to top ]

References:

1.	Ferrlecit Full Prescribing Information, Watson Pharma, Inc.
2.	Data on file. Watson Pharma, Inc.
3.	Seligman PA, Dahl NV, Strobos J, et al. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy. 2004;24(5)574-583.
4.	Nissenson AR, Lindsay RM, Swan S, et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patiens: North American clinical trial. Am J Kidney Dis. 1999;33:471-482.
5.	National Kidney Foundation Dialysis Outcomes Quality Initiative/Kidney Disease Outcomes Quality Initiative. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. III. Iron Support. New York: National Kidney Foundation; 2000.
6.	Beckie Michael, Daniel W. Coyne, Steven Fishbane, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830-1839. or Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830-1839.
7.	Beckie Michael, Daniel W. Coyne, Vaughn W. Folkert, et al. Sodium ferric gluconate complex in hemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant. 2004;19:1576-1580.
8.	Coyne DW, Adkinson NF Jr, Nissenson AR, et al. Sodium ferric gluconate complex in hemodilaysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003;63:217-224.
9.	Sirken GR, Qureshi M, Bloom EJ, et al. Association of iron sucrose and ferric gluconate with the infection rate in chronic hemodialysis patients. Poster presented at: Annual Meeting of the American Society of Nephrology; November 12-17, 2003; San Diego, CA.
10.	Lee GR. Iron deficiency and iron-deficiency anemia. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe’s Clinical Hematology. 10th ed. Baltimore, MD: Williams & Wilkins;1999:979–1010.
11.	Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther. 2001;23:1637–1671.
12.	Jacobs A, Worwood M. Ferritin in serum: clinical and biochemical implications. N Engl J Med. 1975;292:951–956.
13.	Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med. 1964;37:62–70.
14.	Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530–538.
15.	Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217–222.
16.	Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997;30:912–922.
17.	Jacobsson S. Clinical value of serum transferrin measurements. J Int Fed Clin Chem. 2001;13:1–8.
18.	Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis. 1997;30:532–541.
19.	Chiang WC, Tsai TJ, Chen YM, et al. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol. 2002;58:363–369.
20.	NKF-DOQI Anemia Work Group. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 2001;37(suppl 1):S182-S238.
21.	Bolanos L, Castro P, Falcon TG, Mouzo R, Varela JM. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol. 2002;22:67-72.
22.	Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM.A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant. 2001;16:1239-1244.
23.	Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079-1083.
24.	Navarro JF, Teruel JL, Liano F, Marcen R, Ortuno J. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol. 1996;16:268-272.

Safety Information

FERRLECIT is contraindicated in non iron-deficient anemias, in patients hypersensitive to FERRLECIT or its inactive components, or with evidence of iron overload • Hypersensitivity reactions have been reported with injectable iron products • Hypotension has been reported with rapid administration of IV iron • In a single-dose, placebo-controlled safety study (n=1097), the most frequent adverse events occurring after FERRLECIT administration were hypotension, nausea, and vomiting and/or diarrhea • In multiple-dose studies (n=126), the most frequent adverse events, whether or not related to FERRLECIT administration, were nausea, vomiting and/or diarrhea, injection site pain, hypotension, cramps, hypertension, dizziness, dyspnea, and chest pain • Please see full prescribing information for Warnings, Precautions, and Adverse Reactions